Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Black Diamond Therapeutics Inc (BDTX)

$2.09 -0.01 (-0.48%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	124.92M
Revenue (ttm)	70.00M
Net Income (ttm)	22.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	31.96%
Debt to Equity Ratio	0.00

Volume	632,100
Avg Vol	1,297,812
Day's Range	N/A - N/A
Shares Out	57.30M
Stochastic %K	2%
Beta	3.22
Analysts	Strong Sell
Price Target	$9.86

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

245 First Street, 18th Floor, Cambridge, United States

chole1 Jun. 3 at 7:49 PM

$BDTX insiders should be buying hand over fist at these levels!!

2 · Reply

Smazza Jun. 2 at 6:40 PM

$BDTX this stock is so bad

2 · Reply

janed102 Jun. 1 at 4:19 PM

$BDTX https://blackdiamondtherapeutics.com/assets/files/bdth-26388-asco-2026-cohorts-1-2-pk11-upload.pdf

0 · Reply

Autolus_Freakk Jun. 1 at 1:59 PM

$BDTX Soon they will be giving away shares for free plus a 1 year subscription to HBO.. who wants to invest in this SP manipulation

0 · Reply

dontsellatlowprice May. 30 at 7:54 PM

$BDTX https://blackdiamondtherapeutics.com/assets/files/asco-2026-cohort-3-rapid-oral-final-29may2026.pdf The data came out well, but a typical bio-stock wait-and-see. I think it's a question of whether money is fast or not.

1 · Reply

BossTrade May. 30 at 5:44 PM

$BDTX Typical sub $5 bio movement. Might dip even to low 2s All add zones

0 · Reply

Autolus_Freakk May. 29 at 2:40 PM

$BDTX Why does this keep going down?? Its like it's facing bankruptcy or something

2 · Reply

RakeTheProfit May. 28 at 4:34 PM

$BDTX I like this one a lot…

0 · Reply

BossTrade May. 27 at 12:41 PM

$BDTX Share flush, data was great

1 · Reply

laaarsas May. 27 at 10:53 AM

$BDTX Why did it actually drop? How was the data compared to expectations?

0 · Reply

Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 22, 2026, 8:00 AM EDT - 13 days ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 21, 2026, 5:30 PM EDT - 14 days ago

Black Diamond Therapeutics Transcript: Study result

May 21, 2026, 5:30 PM EDT - 14 days ago

Black Diamond Therapeutics Press release: Study result

May 21, 2026, 5:13 PM EDT - 14 days ago

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 21, 2026, 7:00 AM EDT - 14 days ago

Black Diamond Therapeutics Slides: Corporate presentation

May 19, 2026, 8:00 AM EDT - 16 days ago

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

May 7, 2026, 7:30 AM EDT - 4 weeks ago

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Black Diamond Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Black Diamond Therapeutics Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Black Diamond Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Black Diamond Therapeutics Proxy statement: Proxy filing

2026-04-29T10:21:57.000Z - 5 weeks ago

Black Diamond price target raised to $11 from $10 at H.C. Wainwright

Apr 21, 2026, 10:40 AM EDT - 6 weeks ago

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

2026-03-17T11:51:25.000Z - 2 months ago

Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush

2026-03-16T20:05:26.000Z - 2 months ago

Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)

Mar 16, 2026, 4:01 PM EDT - 2 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Black Diamond Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Black Diamond Therapeutics Annual report: Q4 2025

Mar 4, 2026, 1:10 PM EST - 3 months ago

Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 4:01 PM EST - 3 months ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

2026-01-16T11:55:20.000Z - 4 months ago

Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler

Dec 4, 2025, 1:00 PM EST - 6 months ago

Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-03T17:40:19.000Z - 6 months ago

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

2025-12-03T17:35:12.000Z - 6 months ago

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

Dec 3, 2025, 8:00 AM EST - 6 months ago

Black Diamond Therapeutics Transcript: Study Update

Dec 3, 2025, 8:00 AM EST - 6 months ago

Black Diamond Therapeutics Press release: Study Update

2025-12-03T12:11:22.000Z - 6 months ago

Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib

Dec 3, 2025, 7:01 AM EST - 6 months ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 2, 2025, 4:01 PM EST - 6 months ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

2025-11-17T21:50:17.000Z - 7 months ago

Black Diamond Therapeutics assumed with an Overweight at Piper Sandler

2025-11-13T22:25:31.000Z - 7 months ago

Black Diamond Therapeutics files $500M mixed securities shelf

Nov 13, 2025, 7:00 AM EST - 7 months ago

Black Diamond Therapeutics Registration statement: Registration Filing

Nov 12, 2025, 9:00 AM EST - 7 months ago

Black Diamond Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 9:20 AM EST - 7 months ago

Black Diamond Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-06T12:35:52.000Z - 7 months ago

Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)

2025-11-06T12:35:40.000Z - 7 months ago

Black Diamond Therapeutics sees cash runway into 4Q27

Nov 6, 2025, 7:30 AM EST - 7 months ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 7 months ago

Black Diamond Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Black Diamond Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 6:00 PM EST - 7 months ago

Black Diamond Therapeutics Slides: Corporate Presentation

2025-10-15T20:36:00.000Z - 8 months ago

Black Diamond Therapeutics resumed with a Buy at Stifel

2025-09-30T16:30:10.000Z - 8 months ago

Black Diamond Therapeutics initiated with a Buy at Freedom Capital

2025-09-04T09:25:07.000Z - 9 months ago

Black Diamond Therapeutics initiated with a Buy at Guggenheim

2025-09-03T20:15:10.000Z - 9 months ago

Black Diamond Therapeutics initiated with a Buy at Guggenheim

2025-08-11T10:21:34.000Z - 10 months ago

Black Diamond price target lowered to $10 from $12 at H.C. Wainwright

2025-08-07T11:42:25.000Z - 10 months ago

Black Diamond Therapeutics reports Q2 EPS (19c), consensus (23c)

2025-08-07T11:42:19.000Z - 10 months ago

Black Diamond Therapeutics sees cash runway into 4Q27

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Black Diamond Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Black Diamond Therapeutics Quarterly report: Q2 2025

2025-07-01T10:51:03.000Z - 1 year ago

Black Diamond Therapeutics resumed with an Outperform at Raymond James

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:00 PM EDT - 1 year ago

Black Diamond Therapeutics Slides: Corporate Presentation

May 12, 2025, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 9:30 AM EDT - 1 year ago

Black Diamond Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Black Diamond Therapeutics Quarterly report: Q1 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 1:00 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 6, 2025, 4:01 PM EST - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 9:30 AM EST - 1 year ago

Black Diamond Therapeutics Annual report: Q4 2024

Mar 6, 2025, 9:30 AM EST - 1 year ago

Black Diamond Therapeutics Earnings release: Q4 2024

Dec 4, 2024, 3:00 PM EST - 1 year ago

Black Diamond Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 9:45 AM EST - 1 year ago

Black Diamond Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 7:00 AM EST - 1 year ago

Black Diamond Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Black Diamond Therapeutics Earnings release: Q3 2024

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Study Update

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Press release: Study Update

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Slides: Study Update

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Earnings release: Q2 2024

Jun 1, 2024, 10:00 AM EDT - 2 years ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Slides: Corporate Presentation

May 9, 2024, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Earnings release: Q1 2024

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 10, 2024, 12:00 PM EDT - 2 years ago

Black Diamond Therapeutics Slides: FY 2024

Apr 7, 2024, 6:00 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Apr 7, 2024, 11:00 AM EDT - 2 years ago

Black Diamond Therapeutics Slides: FY 2024

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Earnings release: Q4 2023

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Annual report: Q4 2023

Mar 5, 2024, 4:30 PM EST - 2 years ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Quarterly report: Q3 2023

Nov 6, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Earnings release: Q3 2023

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 4, 2023, 12:14 PM EDT - 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 3 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Earnings release: Q2 2023

Jun 29, 2023, 8:57 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 4:23 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Jun 27, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Jun 13, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 7:30 AM EDT - 3 years ago

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Earnings release: Q1 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Apr 17, 2023, 4:01 PM EDT - 3 years ago

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Mar 9, 2023, 7:30 AM EST - 3 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 9, 2023, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Earnings release: Q4 2022

Mar 9, 2023, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Annual report: Q4 2022

Feb 27, 2023, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

Jan 5, 2023, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 12, 2022, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

Nov 14, 2022, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Registration statement: Registration Filing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Quarterly report: Q3 2022

Nov 8, 2022, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Earnings release: Q3 2022

Oct 26, 2022, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

chole1 Jun. 3 at 7:49 PM

$BDTX insiders should be buying hand over fist at these levels!!

2 · Reply

Smazza Jun. 2 at 6:40 PM

$BDTX this stock is so bad

2 · Reply

janed102 Jun. 1 at 4:19 PM

$BDTX https://blackdiamondtherapeutics.com/assets/files/bdth-26388-asco-2026-cohorts-1-2-pk11-upload.pdf

0 · Reply

Autolus_Freakk Jun. 1 at 1:59 PM

$BDTX Soon they will be giving away shares for free plus a 1 year subscription to HBO.. who wants to invest in this SP manipulation

0 · Reply

dontsellatlowprice May. 30 at 7:54 PM

1 · Reply

BossTrade May. 30 at 5:44 PM

$BDTX Typical sub $5 bio movement. Might dip even to low 2s All add zones

0 · Reply

Autolus_Freakk May. 29 at 2:40 PM

$BDTX Why does this keep going down?? Its like it's facing bankruptcy or something

2 · Reply

RakeTheProfit May. 28 at 4:34 PM

$BDTX I like this one a lot…

0 · Reply

BossTrade May. 27 at 12:41 PM

$BDTX Share flush, data was great

1 · Reply

laaarsas May. 27 at 10:53 AM

$BDTX Why did it actually drop? How was the data compared to expectations?

0 · Reply

BossTrade May. 26 at 4:35 PM

$BDTX Nice consolidation before the rip

1 · Reply

BossTrade May. 26 at 3:47 PM

$BDTX Just before you listen to any pikers or paid bashers know that not only this has h2 ‘28 cash runway, but 2+ milestones and recent encouraging readout that makes it a very likely to partner/merge for P3 for its lead indications

0 · Reply

BossTrade May. 26 at 3:41 PM

$BDTX Yeah right lol

0 · Reply

Stef_Gee May. 26 at 3:19 PM

$BDTX Always here to help

0 · Reply

Atlasquantlabs May. 26 at 3:04 PM

$BDTX sorry team I meant to say $BRTX

0 · Reply

TheWideOpenRoad May. 26 at 1:59 PM

$BDTX Added to the Russell 2000 1). Cover before the other shorts cover 2). Wait for the R2K related ETFs to buy 6-9,000,000 shares. 3). Short again at a higher price

0 · Reply

Atlasquantlabs May. 26 at 1:58 PM

$BDTX Same thing here! The float is a little better! But needs volume

0 · Reply

BossTrade May. 26 at 1:10 AM

$AVBP $BDTX Time to load bdtx

1 · Reply

waugusti May. 25 at 2:35 PM

$BDTX Only competition in 1st line non classical EGFR mutations is Arrivent $AVBP. They are running a phase3 trial in 1st line PACC Mutations only. First Patient dosed in Dec 2025. $BDTX is well positioned in this upcoming 2 billion $ market to grab all or half of it. MC $AVBP: 1,25 B MC $BDTX: 0,15 B A buyout might happen before YE after the FDA gives green light for a P3 trial.

1 · Reply

waugusti May. 25 at 2:18 PM

$BDTX

0 · Reply

djgestates May. 25 at 10:46 AM

$BDTX Toxicity with the 200mg pill. Forced to discontinue, reevaluating with the 150mg, pushing everything back 6-9 months. Cash burn a sudden concern.

1 · Reply

Ric_1M May. 24 at 12:15 PM

$GMM $ADTX $NGEN $BDTX $AMSS "The whole secret to winning big in the stock market is not to be right all the time, but to lose the least amount possible when you're wrong." William J. O'Neil

0 · Reply

1.0.0